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Neurologic Complications of FK 506 
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FK 506 is used ,increasingly to prevent rejection i.n ~rgan transplantation. Both expenmental '-3 and chmcal4.5 
studies suggest that FK 506 is a more potent immunosup-
pressive agent than cyclosporine (Cy Al, and there are 
indications that FK 506 may also be les's toxic. b The advent 
of any new agent such as FK 506 promises more effective 
immunosuppression. but also gives rise to the need for 
further study of potential toxic side effects. Indeed. a 
report by Reyes et al7 of two patients who developed 
speech dysfunction while on FK 506 suggests that this 
agent may under certain circumstances produce adverse 
_::....effects on the nervous system. Thus. more information is 
needed about potential nervous system disturbances that 
may occur in association with the clinical use of FK 506 in 
transplant patients. We carried out this study to identify 
the spectrum and frequency of neurologic disturbances 
that may occur in transplant patients receiving FK 506. 
PATIENTS AND METHODS 
Data regarding the toxic effects of FK 506 on the nervous system 
were obtained from three major patient sources: group I consisted 
of those patients in the general transplant population who were 
seen routinely for neurologic events: group 2 comprised a pro-
spective study of 294 consecutive adult recipients: and group 3 
resulted from surveillance of outpatients for possible long-term 
complications of FK 506. The details of these patient groups are 
given below. 
Group 1 
The dav·to-day monitoring of posttransplant patients IS carried 
out by the transplant servIce. and neurologic consultations are 
obtained when disturbances in the nervous system function are 
suspected. Our data were obtained from a retrospective chart 
analysis of documented neurology consult findings. By this 
method. we identified 23 transplant reCipients who developed 
neurologic complications from a total of approXimately 800 reo 
poned transplant patients receiving FK 506 during the same time 
period. These 23 patients consisted of 20 liver transplantations. I 
hean. I kidney. and I combined liver/kidney transplant. 
Group 2 
The 294 adult patients in this group form pan of a wider study 
companng efficacy and side effects of FK 506 and eVA. The 
breakdown of types of organ transplant is as follows: 238 livers. 53 
hearts. 2 double lungs. and 1 heart/lung. These patients were 
studied prospectively. and monitoring was again earned out by 
both the neurology and transplant services. although initial rec-
'ognilion of neurologic problems remained with the transplant 
service. 
Group 3 
This group consisted of 83 patients who were monitored in 
outpatient clinics and who were not primanlx seen by a neurole-
gist: however. if symptoms relating to neurologic function were 
elicited. neurologic follow-up was obtained. Among these pa-
tients. 62 received liver transplants and 21 heart transplants. The 
monitoring period ranged from a few weeks to 2 years. 
Dosage of FK 506 
In the initial phase of treatment. FK 506 was administered IV 
using an intermittent bolus of 0.075 mg/kg over 4 hours every 12 
hours. This dosage was later modified to a continuous IV infusion 
of 0.15 mg/kg administered over 24 hours. While the number of 
days of IV treatment varied among patients. all were eventually 
,witched to an oral dose of 0.15 mg/kg given at 12·hour intervals. 
RESULTS 
A number of neurologic abnormalities were evident in 
patients who received FK 506. ranging from a mild trem-
ulousness. which was the most common finding, to major 
disturbances of neurologic function. Table I identifies the 
types of major and minor abnormalities that have been 
identified and shows their division into major and minor 
types. Major neurologic side effects were identified in 16 
(5.4%) of the 294 prospectively studied patients. generally 
occurred within the first 30 days following transplantation 
(mean onset 12.8 ± 9 days), and were related in many 
instances to high plasma levels of FK 506 (Fig I). Heart 
and lung transplant recipients were less vulnerable to 
complications of this nature. with only 3.6% developing 
nervous system dysfunction. In the liver recipients. there 
was no significant relationship between the development 
of this type of neurologic complication and the preexisting 
bilirubin level or type of liver disease. Patients with 
preexisting hepatic encephalopathy and prolonged graft 
dysfunction seemed to be more prone to neurologic com-
plications. 
Retrospective chart analysis of the patients in group I 
identified 19 patients with major neurologic side effects. 
There were four others who had minor disturbances, two 
with headache and two with severe tremors. Of the major 
disturbances. encephalopathy was the most common fea-
ture, occurring in II patients. Three subjects demonstrated 
focal abnormalities. and one exhibited signs of akinetic 
mutism. Myoclonic reactions were seen in one subject and 
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Fig 1. Average daily bilirubin levels in the two patient groups 
during the first 60 days posttransplantation, trough plasma FK 506 
levels In the same patients, and daily doses of FK 506 are shown. 
A total of 215 patients with no neurotoxicity and 14 patients with 
signs of neurotoxIcity are shown, which do not represent all of the 
prospective patients. 
seizures in three others. In this group, high plasma FK 506 
levels were a common. but not invariable association. 
Neurotoxicity usually develops during the IV phase of 
drug administration. The dose of FK 506 was no higher in 
patients with observed neurotoxicity than in those who 
remained symptom-free. However, in more than 50% of 
those with neurotoxicity, FK 506 trough plasma levels 
were greater than 3 ng/mL (mean value 3.4 :!: 3 ng/mLl, 
with normal upper therapeutic levels being 2.5 ng/mL (Fig 
I). Neurologic function improved after FK 506 levels 
declined. but often with a delay of several days between 
recovery of function and normalization of plasma FK 506 
concentration. Figure 2 shows a representative example of 
one patient'S course of FK 506 levels. 
Akinetic mutism was the most common of the major 
neurologic side effects noted in the prospectively studied 
patients. This condition is charactenzed by an apparent 
state of wakefulness in which the patient may follow the 
examiner with the eyes. but show{i no other evidence of 
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voluntary muscle activity. Motor responses to noxious 
stimuli are very much reduced and often absent. The 
patient is unable to talk and shows no other ability to 
communicate. This clinical presentation was seen sever.' 
days after transplantation and was associated with eith.: 
high plasma FK 506 levels. severe pretransplant hepatiC 
dysfunction. or preexisting disease of the nervous system. 
Temporary withdrawal of reduction in the dose of FK 506 
resulted in improvement in neurologic function. and rein-
troduction of FK 506 was not associated with a recurrence 
of akinetic mutism. 
The encephalopathy was characterized by an initial 
disturbance of consciousness. but. in some cases. agitation 
heralded its onset. Impairment in consciousness ranged 
from a mild lethargy to a severe state of coma, with only 
minimal reaction to painful stimuli. Seizure activity com-
plicated the encephalopathy in two patients. This condi-
tion was generally related to high plasma FK 506 levels 
with improvement occurring after adjustments in drue 
dosage. Return of consciousness lagged behind the falling 
FK 506 levels by several days (Fig 2). Computerized 
tomography studies of the brain carried out in four patients 
demonstrated nonspecific changes in the form of volume 
loss. Recovery of function was the rule following changes 
in FK 506 dosage. 
Seizures developed either as an isolated complication or 
as a component of the encephalopathy and ranged from 
partial motor attacks (focal seizures' to generalized tono-
clonic seizures. Partial complex status epilepsy also devel-
oped in one patient as a feature of the encephalopathy. 
Focal neurologic abnormalities occurred in four pa-
tients. including dysarthria and aphasia in two as previ-
ously described'? hemiplegia in one. and cortical blindness 
in the other one. Magnetic resonance imaging (MRil 
studies obtained in these patients revealed focal changes in 
the white matter. The clinical and MRI findings Improved 
over time. 
The minor neurologic side effects were generally more 
common, occurring in about 20% of the patients. Sleep 
disturbances and tremulousness of the hands were the 
most common findings and tended to be most prominent 
shortly after transplantation. These diminished with time 
and were not associated with high FK 506 plasma levels. 
Table 1. Neurologic Side Effects of FK 5D6 
Major 
Akinetic mutism 
Seizures 
Psychosis 
Encephalopathy 
Focal deficits 
Movement disorder 
Minor 
Tremors 
Headache 
Sleep disturbances 
Nightmares 
Vertigo 
Dysesthesia 
Mood changes 
Photophobia 
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Fig 2. Posttransplant course of 
a 48-year-old cardiac transplant 
recipient. Elevated blood urea ni-
trogen and creatinine during the 
first 2 weeks was related to pen-
operative hypotension with sec-
ondary renal failure. Neurologic 
dysfunction was characterized 
by an encephalopathy with con-
comitant rising plasma FK 506 
level. 
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DISCUSSION 
Our findings indicate that a wide variety of neurologic side 
effects may occur with the use of FK 506, which are similar 
to those associated with CyA.8-12 These effects have been 
classified into major and minor, based on the nature of the 
clinical impact rather than on eventual outcome. The 
major side effects include akinetic mutism. encephalopa-
thy, seizures. and focal neurologic disturbances while the 
minor ones relate to insomnia. visual symptoms. head-
ache, tremors. dysesthesia. and mood changes. 
In evaluating the neurologic impact of FK 506, it is 
important to consider the background medical status of the 
patient. Similar neurologic manifestations are seen in non-
immunosuppressed patients with end-stage liver disease. 13 
suggesting that a predisposition could be present. In addi-
tion. posttransplant liver recipients are likely to develop a 
variety of metabolic and circulatory disturbances and are 
also prone to acute graft rejection. They are often given 
pharmacologic agents that may adversely affect the ner-
vous system. Thus. the clinical picture is compounded by 
a variety of interacting factors that may either individually 
or collectively produce disturbances in neurologic func-
tion. making it difficult to differentiate the specific factors 
operating to produce the neurologic disturbance. The 
medical picture was indeed complex in all our patients: 
however. FK 506 was determined to be contributory. if not 
the cause of the neurologic dysfunction. by a process of 
exclusion of other potential causes of the clinical presen-
tation. It is still possible that additional background distur-
bances contributed in some measure to the neurologic 
syndrome. which could have infiuence~ our early estima-
60 
tion of the neurotoxic effects of FK 506. Moreover. the 
same predisposition of liver recipients to Cy A toxicity has 
been noted. 
Although the major complications of FK 506 neurotox-
icity are much more common in liver transplant recipients. 
heart and lung patients may also develop these neurologic 
side effects. In the two heart recipients who presented with 
posttransplant encephalopathy. there were underlying pre-
disposing conditions. One subject had chronic. progressive 
multiple sclerosis (MS), and the other had been in severe 
cardiac failure. with a prolonged episode of profound 
hypotension perioperatively. Disturbances in the blood-
brain barrier are known to occur in MS.14 and cerebral 
blood flow is known to be abnormal in severe end-stage 
cardiac failure. 15 These conditions may adversely affect 
the blood-brain barrier. thereby producing a relatively 
higher central nervous system (CNS) FK 506 concentra-
tion with resultant clinical effects. Four of the liver recip-
ients with postoperative neurologic dysfunction also ex-
hibited signs of severe hepatic encephalopathy prior to 
transplantation. and an additional four were subject to 
prolonged posttransplant graft dysfunction. 
High plasma levels of FK 506 probably are associated 
with the development of neurotoxicity. and peak plasma 
concentrations are generally higher in patients who exhibit 
signs of nervous system involvement. In our patients. 
neurologic complications were most common when the 
drug was administered IV in bolus form. However. the 
profound neurologic effects were of a temporary nature. 
and all patients improved when the dose of FK 506 was 
reduced or when the agent was temporarily withdrawn. 
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The patient with MS developed akinetic mutism 3 days 
after cardiac transplantation. Although serum FK 506 
levels were not elevated. the drug was nonetheless with-
held and his condition improved. There was no recurrence 
of this acute neurologic dysfunction after subsequent rein-
troduction of FK 506. It is noteworthy that his condition at 
6 months posttransplaIitation with respect to the MS was 
much better than prior to the procedure. We speculate that 
this improvement could be attributed to the beneficial 
effect of FK 506 on the disease process (MS) itself. 
Other immunosuppressi",e drugs were administered. and 
prednisone in doses ranging from 20 to 40 mgld was used as 
adjunctive therapy in patients. Azathioprine was added to 
the therapeutic regimen in 25% of the patients. None of 
these agents was expected to playa major contributing role 
in the development of the particular neurologic syndromes 
that were recorded. although all were described in the 
early days of liver transplantation under azathioprine-
prednisone therapy. 16 
Various laboratory assays were carried out. including 
measurements of serum cholesterol. magnesium. bilirubin. 
and hemoglobin. There was a tendency for the magnesium 
to be on the low side of the normal range. but hypo-
magnesemia was not consistently evident. and there was 
no clear relationship between low magnesium levels and 
FK 506 neurotoxicity as with CyA. 17 
Minor neurologic side effects were most obvious at an 
early stage following transplantation. and there was a 
tendency for these to become less apparent over time. This 
tendency may relate in part to higher serum FK 506 levels 
during the early posttransplantation phase when individual 
patient dosages were titrated. [n some patients. however. 
the abatement of symptoms did not relate to lower FK 506 
levels. suggesting that other mechanisms may have been 
operative in producing an increased tolerance to the drug. 
When comparing FK 506 neurolOxicity with CyA. many 
similarities are apparent. Cy A induces encephalopathy. IU 
akinetic mutism. I:! seizures.~ and focal neurologic signs. II 
Abnormalities have been detected on MRI imaging in 
patients receiving FK 506. IH and similar changes have also 
been evident in this study. However. the abnormalities are 
smaller and localized. unlike those described in patients on 
CyA. CyA-induced neurotoxicity has been reported to 
occur in 25% of patients on this agent.IH but our experience 
with FK 506 suggests that neurotoxicity is less frequent 
with this drug. occurring in only 6% of the prospectively 
studied subjects. Also. in contrast to FK 506. Cy A-
induced side effects have not been reported to show such 
a distinct relationship to high levels of this immunosup-
pressive agent. 
Hypocholesteremia has been implicated as a possible 
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factor related to the development of CyA nervous system 
toxicity. 18 While there is a tendency for FK 506 to lower 
serum cholesterol. there was no clear relationship between 
hypocholesteremia and neurotoxicity in this series of pa-
tients. 
CONCLUSIONS 
The drug FK 506 has the potential to adversely affect the 
nervous system. provoking both major and minor compli-
cations with its use. However. these side effects are 
reversible and usually occur either as a result of high 
plasma FK 506 levels or in association with an underlying 
predisposing condition. A better understanding of the 
clinical pharmacodynamics of FK 506 should result in 
better control of plasma FK 506 levels. which. in tum. 
should reduce the incidence of major neurotoxicity. 
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